Background: The majority of pancreatic cancers are diagnosed at an advanced stage. As surgical resection remains the only hope for cure, more aggressive surgical approaches have been advocated to increase resection rates. Institutions have begun to release data on their experience with pancreatectomy and simultaneous arterial resection (AR), which has traditionally been considered a general contraindication to resection. The aim of the present meta-analysis was to evaluate the perioperative and long-term outcomes of patients with AR during pancreatectomy for pancreatic cancer. Methods: The Medline, Embase, and Cochrane Library and J-East databases were systematically searched to identify studies reporting outcome of patients who underwent pancreatectomy with AR for pancreatic cancer. Studies that reported perioperative and/or long-term results after pancreatectomy with AR were eligible for inclusion. Meta-analyses included comparative studies providing data on patients with and without AR and were performed using a random effects model. Results: The literature search identified 26 studies including 366 and 2243 patients who underwent pancreatectomy with and without AR. All studies were retrospective cohort studies and the methodological quality was moderate to low. Meta-analyses revealed AR to be associated with a significantly increased risk for perioperative mortality [Odds ratio (OR) = 5.04; 95% confidence interval (CI), 2.69-9.45; P < 0.0001; I 2 = 24%], poor survival at 1 year (OR = 0.49; 95% CI, 0.31-0.78; P = 0.002; I 2 = 35%) and 3 years (OR = 0.39; 95% CI, 0.17-0.86; P = 0.02; I 2 = 49%) compared with patients without AR. The increased perioperative mortality (OR = 8.87; 95% CI, 3.40-23.13; P < 0.0001; I 2 = 5%) and lower survival rate at 1 year (OR = 0.50; 95% CI, 0.31-0.82; P = 0.006; I 2 = 40%) was confirmed in the comparison to patients undergoing venous resection. Despite substantial perioperative mortality, pancreatectomy with AR was associated with more favorable survival compared with patients who did not undergo resection for locally advanced disease. Conclusions: AR in patients undergoing pancreatectomy for pancreatic cancer is associated with a poor short and long-term outcome. Pancreatectomy with AR may, however, be justified in highly selected patients owing to the potential survival benefit compared with patients without resection. These patients should be treated within the bounds of clinical trials to assess outcomes after AR in the era of modern pancreatic surgery and multimodal therapy. (Ann Surg 2011;254:882-893) T he majority of pancreatic cancers are diagnosed at an advanced stage. 1,2 As surgical resection remains the only hope for cure From the
for these patients, dedicated pancreatic surgeons have strived for increased radicality to improve resection rates. 3 Fortner 4 originally described a regional pancreatectomy which involved an en bloc total pancreatectomy, radical regional lymph node clearance, combined portal vein resection (Type I) and/or combined arterial resection (AR) and reconstruction (Type II). The combined mortality and morbidity of these procedures, however, were prohibitive. Arterial and portal venous involvement, therefore, was generally seen as a contraindication to resection.
Extended pancreatectomy was another term used to describe a standard or distal pancreatectomy in the setting of aggressive regional nodal clearance, often done concomitantly with portomesenteric venous resection. 5 Although aggressive nodal clearance did not result in increased survival, the feasibility of portomesenteric venous resection was demonstrated. This encouraged a more aggressive approach to increase resectability rates. Later reports demonstrated that survival for patients who undergo limited portomesenteric venous resection was comparable to those undergoing conventional pancreatectomy. [6] [7] [8] As venous resection can, moreover, be carried out safely in experienced hands, major venous involvement has therefore no longer been considered a contraindication to resection. 9, 10 In contrast, major arterial involvement has remained an issue of controversial debate. Appleby 11 described a technique which involved en bloc resection of the celiac axis combined with distal pancreatectomy, and subtotal gastrectomy for locally advanced gastric cancer. This technique was later adapted for locally advanced pancreatic cancer of the body and tail to increase resectability rates and has since been modified. 12 Although arterial involvement requiring resection of the superior mesenteric artery, common hepatic artery (HA) or celiac artery (CA) defines local irresectability according to current guidelines, 10 studies on the outcome of patients who underwent AR for pancreatic cancer are scarce and their results are inconsistent. In such circumstances, a systematic review providing a critical appraisal of the available evidence together with a meta-analysis of the results of existing studies is helpful to obtain more precise estimates of treatment efficacy and safety.
It was therefore the aim of the present systematic review and meta-analysis to evaluate perioperative outcome and long-term survival of patients who underwent resection for pancreatic cancer with combined AR. studies published in English, German, and Japanese. The last search was done on November 16, 2010. The titles and abstracts of the search findings were screened for potentially eligible studies. Full articles, which were considered relevant, were obtained for detailed evaluation and eligible studies were included. All prospective and retrospective studies on perioperative and oncological outcome of patients undergoing pancreatectomy with AR for pancreatic cancer were eligible for inclusion. We excluded comments, letters, articles with less than 5 patients who underwent AR, articles in which no data on outcome from patients with AR could be extracted, and articles which dealt with resection of arteries other than the common HA, proper HA, CA, left and/or right HA, and the superior mesenteric artery (SMA).
Data Extraction and Quality Assessment
Two authors (N.M. and N.N.R.) independently extracted the following data from each identified study: first author, year of publication, study period, sample size, baseline characteristics of the study cohort, kind of vascular resections, vascular reconstruction techniques, extended lymphadenectomy, duration of follow-up, neoadjuvant therapy, adjuvant therapy, and study design. We documented data on the following outcomes: perioperative morbidity and mortality, kind of complications, reoperation rates, stage of disease, resection margin, blood loss, operating time, and hospital stay. To assess oncological value of AR, we extracted data on median survival and survival rates at 1, 3, and 5 years after surgery. For studies offering comparative data, data were extracted separately for both study arms (ie, patients undergoing pancreatectomy with vs without AR).
We applied the risk of bias tool recommended by the Cochrane Collaboration to assess the methodological quality of included studies. 39 For evaluation of nonrandomized studies the criteria proposed by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group (www.gradeworkinggroup.org) were applied. 40, 41, 42 For each included study, the following criteria were evaluated: application of adequate eligibility criteria, adequate measurement of outcomes, adequate control of confounding factors, completeness of follow-up and adequacy of its duration, adequate reporting of outcomes, and absence of other sources of bias. As the use of scales with scores for multiple items that are summed up are discouraged by the Cochrane Collaboration, the aforementioned criteria were used to grade individual studies as high or low risk of bias. 39
Statistical Analysis
The present systematic review and meta-analysis was conducted in accordance with the methodology recommended by the Cochrane Collaboration and the previously published PRISMA statement. 43 Meta-analyses were performed for studies that provided comparative data on outcome of patients who underwent pancreatectomy with and without AR. For studies providing separate data on outcome of patients with AR, with venous resection only and without vascular resection, patients without vascular resection were prioritized as control groups. However, subgroup analyses were performed to compare outcome of patients with arterial and venous resection (see later). Odds ratio (OR) was chosen as effect measure dichotomous data and weighted mean difference (WMD) for continuous data, which reported along with the 95% confidence intervals (CI). As we expected clinical heterogeneity between included studies due to differences with respect to eligibility criteria (study populations), kind of surgical procedures, (arterial) resections and reconstructions, lacking or differing definitions of outcome parameters and differences in the perioperative and oncological management, meta-analyses were performed using a random effects model for more conservative effect estimates. 44 Heterogeneity was assessed with I 2 statistics. 45 This approach describes the proportion of total variation observed between the trials that is attributable to differences between trials rather than sampling error (chance). An I 2 value of more than 50% was considered to indicate high statistical heterogeneity. Reasons for statistical heterogeneity were explored using sensitivity analyses (exclusion of individual studies). Furthermore, subgroup analyses carried out to evaluate the impact of the institution's experience (sample size of patients with AR), improved surgical and perioperative management (year of publication), and study quality (risk of bias) on the results. In addition, subgroup analyses were done comparing outcome of patients with AR to that of patients with venous resection. For the purpose of subgroup analyses, continuous data were dichotomized using the median value. Presence of publication bias was evaluated using Funnel plot analyses. 46 Meta-analyses were carried out using Review Manager Version 5.0 software (Copenhagen: The Nordic Cochrane Centre; The Cochrane Collaboration, 2008).
RESULTS
The literature search yielded a total of 726 studies. After detailed assessment, 26 studies were detected that matched the eligibility criteria for inclusion in this systematic review ( Fig. 1 ). In these studies, the outcome of patients who underwent pancreatectomy with AR was compared with the entire population as a whole in 2 studies, 13, 18 reported without any control group in 5 studies, 14, 17, 20, 26, 31 and compared with patients with pancreatic resection who did not receive AR in 19 studies. 15, 16, 19, [21] [22] [23] [24] [25] [27] [28] [29] [30] [32] [33] [34] [35] [36] [37] [38] In 2 cases, data were extracted from 2 reports of the same institution. 15, 22, 47, 48 The identified studies were conducted in 7 countries (Japan, United States, Germany, China, Korea, Italy, and Belgium) and were published between 1977 and 2010. In total, these 26 studies included 2609 patients in whom pancreatic resection was performed with 366 (14.0%) of these patients who underwent concomitant AR ( Table 1 ). The median number of patients undergoing pancreatic cancer resections reported per publication during the study period was 67 and that of patients undergoing AR was 12.5 . Funnel plot analysis on the outcomes of perioperative mortality and 1-year survival did not indicate relevant publication bias (data not shown). Methodological quality of the identified studies was found to be moderate to low. All studies were retrospective analyses and only 4 studies were graded with a low risk of bias. 15, 16, 22, 32 
Perioperative Outcome
The patient characteristics and perioperative outcomes of patients who underwent pancreatectomy with and without concomitant AR are summarized in Tables 2 and 3 .
Data on operating time were available from 11 studies including 148 patients with AR. The median operating time in these studies ranged from 210 25 to 690 minutes. 36 Meta-analysis of the 6 studies that provided comparative data revealed operating time to be significantly prolonged in patients undergoing pancreatectomy with AR (WMD = 59.24; 95% CI, 14.67-103.82; P = 0.009; I 2 = 86%). Sensitivity analysis removing individual studies did not indicate heterogeneity of being caused by a single study. Eight studies on 106 patients with AR provided information on intraoperative blood loss. The median amount of blood loss in these reports ranged from 300 mL 31 to 4500 mL. 36 Meta-analysis including 4 studies with comparative data showed a significant difference of intraoperative blood loss in favor of patients without AR (WMD = 438.16; 95% CI, 206.17-670.14; P < 0.001; I 2 = 88%). The observed heterogeneity was resolved in the sensitivity analyses excluding the study by Wu et al (WMD = 1720.38; 95% CI, 1150.93-2289.82; P < 0.001; I 2 = 0%). Meta-analysis of available data on patients hospital stay indicated a prolonged stay for patients with AR (WMD = 7.97; 95% CI, 1.56-14.38; P = 0.01; I 2 = 67%). Sensitivity analysis by removal of individual studies did not indicate heterogeneity of being caused by a single study.
Perioperative morbidity rates of patients with AR were reported in 14 studies including 201 patients and ranged from 16.7% to 100% (median 53.6%). Information regarding morbidities directly attributable to AR was available for 141 (38.5%) patients. Of these, a total of 24 (17.0%) patients experienced complications involving bleeding, vascular thrombosis, and/or ischemic complications to the liver/stomach. Meta-analysis of the results of 7 studies providing comparative data showed perioperative morbidity to be significantly increased in patients with AR (OR = 2.17; 95% CI, 1.26-3.75; P = 0.006; I 2 = 35%). Reoperation rates ranged from 0% to 75.0% in the 15 studies with available data on 212 patients with AR. Comparative data on reoperation rates of patients who underwent pancreatectomy with and without concomitant AR showed a significant difference in favor of the latter group with moderate statistical heterogeneity (OR = 3.28; 95% CI, 1.68-6.41; P < 0.001; I 2 = 33%). Twenty-two studies provided data on perioperative mortality of 291 patients with AR. The median mortality rate across these studies was 11.8% (range: 0%-45.5%). One should, however, note that in some studies the in-hospital mortality was reported, 19, 23, 28, 37, 38 whereas in others the 30-day mortality, 15, 18, 22, 24 60-day mortality, 33 or 90-day mortality 25 was reported. Moreover, some authors documented the combined 30-day or 60-day mortality and in-hospital mortality 13, 16, 29 and others did not specify or report the kind of mortality experienced. 14, 17, 20, 21, 26, 27, [30] [31] [32] [34] [35] [36] Comparative data on perioperative mortality were available for 14 studies. Inclusion of these ExDP (7) CA + CHA (7) None studies in a meta-analysis revealed the risk of perioperative mortality in patients with AR of being 5 times the risk of patients who underwent pancreatectomy without AR (OR = 5.04; 95% CI, 2.69-9.45; P < 0.0001; I 2 = 24%) (Fig. 2) . Subgroup analyses confirmed the less favorable perioperative outcome of patients with AR (Table 4) . Remarkably, the poor perioperative outcome of patients with AR was also present in the comparison to patients with venous resection (OR = 8.87; 95% CI, 3.40-23.13; P < 0.0001; I 2 = 5%) ( Fig. 3 ).
Oncological Outcome
Histological evidence of arterial invasion was detected in 70 (44.0%) of 159 arterial specimens in 11 studies providing this information. The median arterial invasion rate reported in these studies was 26.1% (range: 0%-100%). Overall, resection margins were negative in 1432 of 1914 (74.8%) patients in 17 studies providing this information. The median rate of R0 resection reported in 15 studies including 209 patients with AR was 60.0% (13.3%-100%). The difference in the R0 resection rate in the meta-analysis comparing studies on patients with and without AR failed to reach statistical significance (OR = 0.65; 95% CI, 0.29-1.42; P = 0.28; I 2 = 60%). Sensitivity analysis by exclusion of the study by Boggi et al indicated a significantly lower R0 resection rate in patients with AR with low heterogeneity (OR = 0.44; 0.25-0.77; P = 0.004; I 2 = 19%).
Comparative data on lymph node metastases could be obtained for 6 studies including 89 patients with AR. Meta-analysis of these studies revealed no difference regarding the incidence of lymph node metastases in patients with and without AR (OR = 1.39; 95% CI, 0.85-2.27; P = 0.19; I 2 = 0%).
To evaluate the oncological value of AR during pancreatectomy for pancreatic cancer survival of patients at 1, 3, and 5 years was analyzed. The median 1-, 3-, and 5-year survival rates of patients who had AR were 49.1% (range: 16%-83%), 8.3% (range: 0%-30%), and 0% (range: 0%-42%), respectively. In the meta-analyses including all studies providing comparative data there was a significantly reduced chance of 1-year survival for patients with pancreatectomy and concomitant AR (OR = 0.49; 95% CI, 0.31-0.78; P = 0.002; Fig. 4A) . Subgroup analyses showed that this difference persisted even when compared with patients with pancreatectomy and venous resection (OR = 0.50; 95% CI, 0.31-0.82; P = 0.006; I 2 = 40%) ( Table 4 ). Meta-analyses of the 12 studies with comparative data on 3-year survival rates also showed less favorable outcome of patients with AR (OR = 0.39; 95% CI, 0.17-0.86; P = 0.02; I 2 = 49%) (Fig. 4B ). Sensitivity analysis revealed heterogeneity to be explained completely by the study by Boggi et al (OR = 0.32; 95% CI, 0.17-0.59; P < 0.001; I 2 = 0%). In line with the findings for pa-tients' 1-and 3-year survival, meta-analysis on 5-year survival rates demonstrated significantly worse outcome of patients with AR with no heterogeneity (OR = 0.30; 95% 0.15-0.60; P < 0.001; I 2 = 0%). Due to the less favorable perioperative and long-term outcome of pancreatic cancer patients undergoing pancreatectcomy with versus without concomitant AR, further analyses were performed comparing oncological outcome of patients with AR to that of patients who did not undergo resection due to locally advanced pancreatic cancer. These analyses were performed following intention-to-treat principles (ie, including perioperative deaths) to consider the operative risk of patients undergoing AR compared with patients who did not receive surgical resection. Owing to the noncontrolled design of the included studies, however, one should note that patients who did not undergo resection might still have had more advanced tumors with a worse progonosis per se compared with patients who underwent pancreatectomy with AR. Comparative data on patients' 1-and 2-year survival were available for 6 studies. 15, 20, 33, 35, 36, 47 Meta-analysis of these studies revealed a higher chance of 1-year survival (OR = 3.02; 95% CI, 1.13-8.11; P = 0.03; I 2 = 70%) for patients undergoing AR, whereas the difference in 2-year survival did not reach statistical significance (OR = 6.09; 0.32-117.36; P = 0.23; I 2 = 78%). The high heterogeneity was caused by the study by Wang et al. Sensitivity analysis excluding this study revealed a statistically highly significant benefit in survival at 1 year (OR = 4.28; 95% CI, 2. 16-8.50 ; P < 0.0001; I 2 = 28%) and 2 years (OR = 19.65; 95% 5.20-74.18; P < 0.0001; I 2 = 0%) for patients undergoing AR compared with patients with no resection.
DISCUSSION
The present study for the first time systematically summarizes the available evidence on outcome of patients with pancreatic cancer undergoing pancreatectomy with concomitant AR. The findings clearly show the perioperative outcome of these patients to be significantly impaired when compared with that of patients receiving conventional pancreatectomy without AR. Moreover, pancreatectomy with versus without concomitant AR is associated with significantly worse long-term survival.
Although the presence of distant metastases and tumor encasement of the SMA or the CA > 180 • are considered the main criteria to define unresectable disease in patients with pancreatic cancer according to current guidelines, 10 there is limited data in the literature to support these criteria. The advances in the field of pancreatic surgery that improved patients' perioperative outcome, together with the poor survival of patients who do not undergo surgical resection, have therefore fueled ongoing debates regarding the value of more radical surgical approaches to achieve tumor extirpation in patients without distant spread. Among these surgical techniques the resection and reconstruction of major peripancreatic arteries is particularly controversial, though the available studies on pancreatectomy with AR present small series of patients and their results are inconsistent. The performed systematic literature search identified a total of 26 studies with a median number of 12.5 patients who underwent AR. Under these circumstances a pooled analysis of the results from different studies may provide a more precise estimate regarding the efficacy and safety of AR for pancreatic cancer.
Evaluation of patients' perioperative outcome revealed a significant increase in the risk of perioperative mortality and morbidity as well as reoperation for patients undergoing pancreatectomy with AR. These data confirm the need for AR as a contraindication to resection for pancreatic cancer. One should note that assessment of morbidity in the present analysis was complicated due in large part to the differences in reporting and the lack of studies offering direct comparisons between patients with and without AR that left only 7 studies for pooled analysis. 15, 16, 19, 23, 29, 34, 37 It is difficult to discern the impact of the local invasiveness and need for extended resections of advanced tumors on mortality rates as opposed to the impact of arterial involvement per se, as very few studies reported on complications directly related to AR and reconstruction. A considerable proportion of patients with AR also received extended lymphadenectomy and simultaneous mesenterico-portal venous resection. Although randomized controlled trials and various cohort studies did not indicate increased mortality associated with extended lymphadenectomy [49] [50] [51] or venous resection, 48, 52 there is little or no data on the impact of these techniques on patients undergoing pancreatectomy with AR. Subgroup analyses of our data, however, confirmed increased perioperative mortality after AR even in the comparison to patients undergoing venous resection, and thus suggest AR as the actual risk factor for perioperative death after pancreatectomy.
In the absence of alternative therapies, the unfavorable perioperative outcome of pancreatic cancer patients associated with AR may in theory be justified by a marked benefit in overall survival. To evaluate patients' oncological outcome, we analyzed long-term survival across available studies after exclusion of patients who deceased in the perioperative period. These analyses still revealed overall survival of patients with AR to be significantly worse when compared with that of patients undergoing pancreatectomy without AR. Although vascular invasion may be considered an indicator of aggressive tumor biology, the subgroup analyses also demonstrated significantly lower long-term survival of patients with AR compared with patients who underwent venous resection. Owing to the frequency of simultaneous arterial and venous resection in the identified studies, one might, however, speculate that the less favorable outcome of patients with AR in these uncontrolled studies is rather related to the more advanced tumors with a higher risk of incomplete (R1) tumor resection and a higher incidence of lymph node metastases, which represent well-known prognostic markers in patients with pancreatic cancer. [53] [54] [55] This hypothesis is, however, not supported by the results of the present meta-analysis showing no significant difference in the incidence of R1 resection and lymph node metastases between patients with and without AR. In the absence of randomized studies the reasons for less favorable survival of patients undergoing AR for pancreatic cancer therefore remain unclear. Despite poor long-term survival after AR and considering substantial perioperative mortality, one should note that the present meta-analysis revealed significantly better survival for these patients when compared with those who did not undergo surgical tumor resection. Because of the noncontrolled design of the included studies, patients who did not undergo resection might still have more advanced tumors with a worse prognosis compared to patients with pancreatectomy with AR. Furthermore, the kind of palliative chemotherapy for the nonresected group might have been suboptimal. The results of these analyses must therefore be interpreted very cautiously. They may still be helpful for patient counseling and justify AR in a highly selected subgroup of patients with a strong desire for aggressive therapy. Criteria to select patients for AR should include patients age (eg, < 55 years), comorbidities and performance status (eg, ECOG score 0 or 1), patient preference and feasibility of the procedure (ie, extent and location of the tumor, suitability of the artery proximal and distal to the tumor for reconstruction, adequate collateral blood supply via the SMA, pancreatoduodenal arcades and gastroduodenal artery for patients undergoing resection of the CA and common HA, respectively).
Although the present study represent the most comprehensive analysis of the perioperative and long-term outcome of patients with pancreatic cancer undergoing pancreatectomy with AR, one should consider that the aggregate study population of patients with AR was rather small and heterogenous with respect to the performed surgical procedures, ARs and reconstructions. Despite these and further sources of heterogeneity such as differences in the institution's experience and perioperative management, statistical heterogeneity was found to be moderate to low. Furthermore, the performed sensitivity and subgroup testing confirmed the finding of a less favorable outcome after AR. Owing to the lack of controlled, clinical trials, the present meta-analysis exclusively included retrospective, uncontrolled studies with an inherent risk of bias. Although randomized controlled trials represent the preferred study design to evaluate effectiveness and safety of a therapeutic intervention, random allocation of patients with arterial involvement to resection and no resection appears hardly feasible and may not be justified on the basis of the results of the present analysis. As safety of pancreatectomy with concomitant AR remains an important concern, these patients should be treated primarily within the bounds of clinical trials with the aim to assess outcomes after AR in the era of modern pancreatic surgery and multimodal therapy. Importantly, these studies should evaluate patients' quality of life after pancreatectomy with AR. Furthermore, a centralized patient registry with prospective patient enrollment might represent a valuable approach to generate more valid data on the value of AR in the surgical management of patients with pancreatic cancer.
In conclusion, the present study provides evidence that pancreatectomy with concomitant AR for pancreatic cancer is associated with poor perioperative outcome and long-term survival and thus confirms the need for AR as a contraindication to resection for pancreatic cancer. The survival benefit offered by pancreatectomy with AR compared to palliative therapy without tumor resection may, however, justify AR in highly selected patients, if it is carried out at specialized institutions. Owing to the limited data available so far, the operative and oncological results of these patients should be documented in centralized patient registries in a prospective fashion.
